LYPHOMED GALLIUM NITRATE NDA TO BE FILED IN SEPTEMBER
Executive Summary
LYPHOMED GALLIUM NITRATE NDA TO BE FILED IN SEPTEMBER for treatment of cancer-related hyper-calcemia, the company announced July 7. The drug is being developed under a research agreement with patent holder Memorial Sloan-Kettering Cancer Center, which has granted LyphoMed exclusive worldwide manufacturing and marketing rights. "Gallium nitrate substantially reduces bone loss, while currently available therapies are far less effective in treating this condition and are excessively toxic," the release states. "Under the research agreement, LyphoMed will support continuing clinical research on gallium nitrate and will undertake the development of an oral form of the drug." The company said it is also planning to file an NDA for treatment of bone metastases "at a later point in time." The agreement with Sloan-Kettering marks another step in the hospital marketer's move into the brand name drug area through the leveraging of its core micronutrient and generic drug business. LyphoMed already markets one proprietary product, Pentam 300, and has at least five more under development, four as orphan drugs. At an Alex Brown health care seminar in May, LyphoMed Senior VP Richard Weiland predicted that the firm may eventually split into two divisions, one for multi-source and one for brand name products ("The Pink Sheet" May 18, T&G-6). Toward that end, the firm's specialty detail force, now at 12 reps, will be expanded to 30 by year-end. Through agreements with NovoPharm and Vestar, LyphoMed has also moved into two other new areas in 1987, oral products marketed to hospitals and liposome-delivered cancer drugs, respectively.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth